ArticleFrontiers in pharmacology2021
Buddleoside-Rich
Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 27 citations in OpenAlex.
- Ultrasound-assisted extraction optimization of Fructus Tribuli polysaccharides: How stir-frying processing alters structures and enhances antihypertensive efficacy.Ultrasonics sonochemistry · 2026Article
- Integrating Animal Experiments, Bioinformatics and Molecular Dynamics Stimulations to Explore the Potential Mechanism of Songyang Duanwu Tea Improving Metabolic Syndrome.Combinatorial chemistry & high throughput screening · 2026Article
- The role of chrysanthemum phytochemicals in neural tube development: a narrative review of underlying mechanisms.Frontiers in cell and developmental biology · 2026Review
- Atractylenolide III as a novel therapeutic strategy for gastric ulcer: mechanistic insights and investigation of molecular targets.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- LC-MS/MS-guided separation of guaiacolane-type sesquiterpenes with anti-inflammatory activities fromRSC advances · 2025Article
- Buddleoside alleviates nonalcoholic steatohepatitis by targeting the AMPK-TFEB signaling pathway.Autophagy · 2025Article
- Microalgae-based bacteria for oral treatment of ASD through enhanced intestinal colonization and homeostasis.Theranostics · 2025Article
- Single-cell transcriptional profiling revealed the protective effects of Buddleoside in sepsis-associated acute liver injury.Frontiers in immunology · 2025Article
- Buddleoside-rich Chrysanthemum indicum L. extract modulates macrophage-mediated inflammation to prevent metabolic syndrome induced by unhealthy diet.BMC complementary medicine and therapies · 2024Article
- Article
- Water Extract ofNutrients · 2023Article
- Beneficial effects of Panax notoginseng (Burkill) F. H. Chen flower saponins in rats with metabolic hypertension by inhibiting the activation of the renin-angiotensin-aldosterone system through complement 3.BMC complementary medicine and therapies · 2023Article
- Efficacy and safety of Qiangli Dingxuan tablet combined with amlodipine besylate for essential hypertension: a randomized, double-blind, placebo-controlled, parallel-group, multicenter trial.Frontiers in pharmacology · 2023Article
- The genusFrontiers in plant science · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As the number of patients with metabolic hypertension (MH) is increasing, there is an essential require for global measures to prevent and treat MH. Flavonoids such as buddleoside (BUD) from
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.